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Abstract 
Background: Clinical risk scores and machine learning models based on routine laboratory values could assist in 
automated early identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients at risk for 
severe clinical outcomes. They can guide patient triage, inform allocation of health care resources, and contribute to 
the improvement of clinical outcomes.
Methods: In- and out-patients tested positive for SARS-CoV-2 at the Insel Hospital Group Bern, Switzerland, between 
February 1st and August 31st (‘first wave’, n = 198) and September 1st through November 16th 2020 (‘second wave’, 
n = 459) were used as training and prospective validation cohort, respectively. A clinical risk stratification score and 
machine learning (ML) models were developed using demographic data, medical history, and laboratory values taken 
up to 3 days before, or 1 day after, positive testing to predict severe outcomes of hospitalization (a composite end-
point of admission to intensive care, or death from any cause). Test accuracy was assessed using the area under the 
receiver operating characteristic curve (AUROC).
Results: Sex, C-reactive protein, sodium, hemoglobin, glomerular filtration rate, glucose, and leucocytes around the 
time of first positive testing (− 3 to + 1 days) were the most predictive parameters. AUROC of the risk stratification 
score on training data (AUROC = 0.94, positive predictive value (PPV) = 0.97, negative predictive value (NPV) = 0.80) 
were comparable to the prospective validation cohort (AUROC = 0.85, PPV = 0.91, NPV = 0.81). The most successful 
ML algorithm with respect to AUROC was support vector machines (median = 0.96, interquartile range = 0.85–0.99, 
PPV = 0.90, NPV = 0.58).
Conclusion: With a small set of easily obtainable parameters, both the clinical risk stratification score and the ML 
models were predictive for severe outcomes at our tertiary hospital center, and performed well in prospective 
validation.
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Background
Coronavirus disease 19 (COVID-19) is an infectious dis-
ease caused by the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). First identified in Wuhan, 
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resulted in a pandemic with over 55 million cases and 
over 1.6 million deaths by early of November 2020 [2].
A large proportion, approximately 40–45%, of infected 
patients show little or no symptoms, [3] and, depending 
on the study, ICU admission rates are estimated between 
5 and about 30% of hospitalized patients [4]. Develop-
ment of individual clinical courses is not always predict-
able and, together with the sheer number of patients 
at-risk for critical or fatal outcomes, this poses challenges 
in patient triage, allocation of health care resources, and 
utilization of intensive care facilities [5, 6].
There have been efforts to develop predictive scores 
and algorithms to address these needs. Given the hetero-
geneity in symptoms on presentation and the potential 
outcomes, [7, 8] it is not surprising that many of the tools 
proposed so far have relied on complex sets of param-
eters or specialized laboratory markers. The recently 
published COVID-19 Acuity Score (CoVA) developed 
from electronic health record (EHR) data of out-patients 
in the Boston area (n = 9381), for instance, contains 30 
items, including presence of intracranial hemorrhage 
and hematological malignancy [9]. While it has been 
shown to predict hospitalization, critical illness, and 
death with accuracies of 0.76–0.93 for the area under the 
receiver operating characteristic (AUROC, ranging from 
0 to 1 with a value of 0.5 indicating no class separation 
above randomness), only 15% (n = 1404) of the cases 
in the development cohort had a confirmed positive 
SARS-CoV-2 test. Del Valle et  al. described correlation 
between prognosis and serum interleukin (IL)-6, IL-8, 
tumor necrosis factor (TNF)-α and IL-1β, which, though 
predictive, are expensive non-routine tests [10]. Several 
tools also rely on chest x-ray findings, some of which use 
machine learning (ML) to automatically classify digital 
images [9, 11, 12]. The value of chest x-rays, however, 
has been called into question, as no lesions specific for 
COVID-19 have so far been identified, and images may 
appear normal despite pulmonary symptoms [13].
The aim of the present study was to develop eas-
ily deployable screening tools for early identification of 
COVID-19 patients at risk for severe outcomes, defined 
as a composite endpoint consisting of either requiring 
treatment in an intensive care unit (ICU), or death from 
any cause. The tools include a clinical prediction rule 
scoring system intended for bedside use by practitioners, 
and several ML models suitable for deployment in EHR 
systems for automated monitoring. Potential applications 
include real-time screening of in-patients to gauge future 
demand for intensive care, and decision support at point-
of-care in patient triage. The investigated covariates, 
e.g. medical history, patient demographics, and labora-
tory values often routinely assessed on admission, such 
as blood glucose, sodium, or C-reactive protein, were 
chosen due to their ease of availability. We trained mod-
els using in- and out-patients seen at our tertiary hospital 
during spring and summer of 2020 (‘first wave’). To con-
firm the findings were generalizable, we validated them 
prospectively using the cases of the ‘second wave’ during 
autumn 2020.
Methods
Study population and training cohort
The study was approved by the Cantonal Ethics Commit-
tee of Bern (Project-ID 2020-00973), and carried out at 
the Insel Hospital Group (IHG), a tertiary hospital and 
the biggest health care provider in Switzerland with six 
locations and about 860000 patients treated per year. For 
the training cohort, we considered all individuals who 
tested positive for SARS-CoV-2 at the IHG between Feb-
ruary 1st through August 31st 2020–covering the ‘first 
wave’ of COVID-19 in the country, and who did not 
reject the general research consent. For patients with no 
registered general research consent status, a waiver of 
consent was granted by the ethics committee. Patients 
who objected to the general research consent of the IHG, 
or who tested negative for SARS-CoV-2, were excluded 
from the study. Participation in other trials (incl. COVID-
19 related treatment studies) was not an exclusion crite-
rion and was not recorded separately. For SARS-CoV-2 
detection, a reverse-transcriptase polymerase chain 
reaction (RT-PCR) assay was used on nasopharyngeal 
swabs as a diagnostic test. Detailed information on the 
selection of the study population is provided in Fig.  1. 
All patients were discharged or had died by the time of 
model development.
For the development of the score and the ML models, 
patients were classified according to their disease sever-
ity (the primary outcome), with the worst outcome at any 
point after the first positive diagnosis determining the 
class:
– Non-severe Patients who tested positive for SARS-
CoV-2, but were neither admitted to the ICU nor 
died of any cause during their hospital stay (classified 
as ‘negative’).
– Severe Composite outcome for patients who tested 
positive for SARS-CoV-2 and required ICU admis-
sion at any stage during the disease and/or died of 
any cause during their hospital stay (classified as 
‘positive’).
Given that the study was retrospective and observa-
tional, sample sizes were dictated by the dynamics of the 
pandemic in the greater Bern region. Consequently, no 
formal power calculations were performed a priori.
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Validation cohort
As independent time-sliced validation cohort, patients 
from the ‘second wave’ (first positive test for SARS-
CoV-2 between September 1st and November 16th 2020) 
were identified. Exclusion criteria and allocation to sever-
ity group were the same as for the training cohort. For 
patients from the validation cohort with no registered 
consent status, a waiver of consent was granted by the 
ethics committee. All patients were discharged or had 
died by the time the validation was performed.
Data preparation
We selected the 20 most frequently measured laboratory 
values (see Additional file 1: Figure S1–1). For highly cor-
related variables, the most easily obtainable one was used 
in the study (e.g. for erythrocyte count and hemoglobin, 
the latter was chosen because its determination does not 
require flowcytometric methods). We then selected those 
variables that were either positively or negatively corre-
lated with the outcome (severe or non-severe COVID-
19) as identified by pairwise Pearson’s correlation.
Since our goal was to develop tools for early identifi-
cation of at-risk patients, we only considered laboratory 
values from the 3 days leading up to the first positive 
RT-PCR, as well those from the day following the posi-
tive test–corresponding to the intended time of use of the 
score and models. If multiple measurements were avail-
able for a given parameter, we chose the most extreme 
values so as to minimize bias from treatment effects. 
Missing data (3% of all data points, most frequently esti-
mated glomerular filtration rate (eGFR)) were imputed 
using the k-nearest neighbor algorithm.
Demographic data were extracted from the EHR and 
included age at time of COVID-19 test, sex, weight, 
height, and body mass index (BMI). Again, for time-
varying covariates, we chose the values available closest 
to the first positive RT-PCR test. Two authors manually 
screened the EHR for the medical history of patients in 
the training cohort. Specifically, we assessed substance 
use (nicotine, alcohol), cardiovascular diseases (arte-
rial hypertension, coronary and chronic heart disease, 
stroke, other cardiovascular disease), pulmonary diseases 
(asthma, chronic obstructive pulmonary disease (COPD), 
other pulmonary disease), type II diabetes, and cancer.
As ethnicity is unfortunately not systematically col-
lected in the EHR, and we were not able to retrospec-
tively obtain these data, we were unable to evaluate its 
effect on disease severity. Furthermore, even though 
other studies suggested the importance of proteom-
ics and metabolomics [14–16], these data were also not 
available for the patients anaylzed, and could therefore 
not be included in the research.
COVID‑19 severity assessment score
The training cohort was randomly divided into an 
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Fig. 1 Flowchart of training and validation cohort used for model and score development
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validation (20%) set, stratified for severe and non-
severe cases in each set. Using the training set, the 
parameters were plotted against the severity using 
the local polynomial regression fitting (LOESS) func-
tion [17]. In combination with the splits provided by 
the Decision Trees (DTI; see below), these graphs were 
used to define the cut-offs for continuous parameters. 
For the included laboratory values, cut-offs were set as 
close as possible to the upper or lower normal range 
values, to allow for an early identification of patients 
at risk. Based on the cut-offs, the continuous param-
eters (i.e. laboratory values) were converted into cat-
egorical parameters. For categorical parameters (e.g. 
sex), the existing levels were kept. Score points of each 
level and each parameter were obtained by fitting a 
logistic regression model. We examined several dif-
ferent parameters and combinations thereof based on 
mechanistical plausibility. As we aimed to develop an 
easy and quick score with as few parameters as pos-
sible, we excluded parameters, which were only weakly 
correlated with the investigated outcome (Pearson cor-
relation coefficients between -0.4 and 0.4, see Addi-
tional file  1: Figure S1–2), as we expected them to 
not improve the overall performance of the score as 
assessed by the AUROC. From the remaining param-
eters, we excluded parameters, which were correlated 
(hemoglobin was correlated to erythrocytes, hemato-
crit, and mean corpuscular haemoglobin concentra-
tion) or described the same organ system (eGFR and 
creatinine). For two parameters (red cell distribution 
width and mean platelet volume) no suitable cut-offs 
could be defined and so they were excluded. The total 
score was calculated for each patient in the training 
and internal validation set.
In a second step, the probability of a severe outcome 
was determined by fitting the total multivariable score 
to the observed outcome using logistic regression. To 
quantify the predictive value of the score, the AUROC 
was calculated. As the results of the fitting depend on 
the splitting of the training and validation set, the steps 
described above were repeated with 30-fold cross-
validation (we chose this number to obtain the same 
overall number of repeats as with the repeated cross-
validation of the  ML models, see below). The final 
score points with which each parameter contributes to 
the total score was the median of the 30 folds. This step 
also served as internal cross-validation. As external 
validation, we evaluated patients from the validation 
cohort (patients tested positive for COVID-19 between 
September 1st and November 16th, 2020). We used the 
above score, predicted the outcome for the external val-
idation cohort, and compared this with the actual out-
come, then calculated the AUROC.
Machine learning models
In a further step, different statistical and ML models 
were fitted to the dataset. First, we used standard mul-
tivariate logistic regression (LogReg).Then we fitted 
machine learning models, which mimic human decision 
processes, either rule-based as decision tree induction 
(DTI) using a variation of classification and regression 
trees (CART) and random forest (RF, an aggregation of 
multiple decision trees), or based on similarities such 
as k-nearest neighbor (kNN). Lastly, we applied high-
dimensional, complex algorithms known to generate 
robust classification models such as AdaBoost, support 
vector machines (SVM) with linear kernel, and multilayer 
perceptrons (MLP) [18]. Parameter values were scaled 
to range between 0 to 1, except for DTI and RF, where 
the original parameter values were used. Model weights 
were calculated to account for the slightly unbalanced 
outcomes. All models were trained using internal three 
times repeated tenfold cross-validation. An external pro-
spective validation of these models was performed on the 
validation cohort to compare performance parameters of 
the internal and the external validations.
Software and statistical tests
Data wrangling, analysis and visualization was performed 
in GNU R (version 4.0.2, R Foundation for Statistical 
Computing, http://www.R-proje ct.org, Vienna, Aus-
tria). Standard statistics, e.g. logistic regression, LOESS 
function, Chi square test, Wilcoxon rank sum test, were 
conducted using the stats package (version 4.0.2). For 
ML models the packages caret (version 6.0–86), rpart 
(version 4.1–15), randomForest (version 4.6–14), DMwR 
(version 0.4.1), e1071 (version 1.7–4), and RSNNS (ver-
sion 0.4–12) were used.
Statistical significance levels were determined using 
the Wilcoxon rank sum test for non-normally distributed 
parameters, as confirmed by the Shapiro-Wilk test, and 
the Chi square test for categorical parameters.
Results
Study population and training cohort
A total of 16418 patients were screened for SARS-CoV-2 
between February 1st and August 31st 2020, of which 
740 rejected general research consent. Of the 577 eligible 
patients testing positive (419 out-patients and 158 requir-
ing hospitalization), sufficient data was available for 198 
(no laboratory analysis performed in 378 cases and no 
access to the EHR in one case) which made up the final 
training cohort, and were grouped based on the outcome 
in 63 severe and 135 non-severe cases (Fig. 1). Mean time 
to ICU admission in the severe group was 1.9 days (range: 
3 days before COVID-19 test and 45 days after positive 
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RT-PCR test), and the mean time to death (n = 25) was 
22.1 days (range: 1 to 79 days after positive RT-PCR test).
As shown in Table 1, patients with severe disease were 
predominantly older and male. While there was no differ-
ence in substance use (nicotine or alcohol) or pulmonary 
disorders, there was an association with more cardiovas-
cular comorbidities (arterial hypertension, cardiomyo-
pathy and congestive heart failure, and coronary heart 
disease, but not stroke or other cardiovascular diseases) 
and type II diabetes. We saw no difference in the preva-
lence of cancer.
After parameter selection, the following laboratory 
parameters were ultimately included as laboratory covar-
iates: C-reactive protein (CRP), sodium, hemoglobin, 
estimated glomerular filtration rate (eGFR) according to 
the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation (provided by the EHR system), glu-
cose, and leucocytes. For demographics, the sex of the 
patient was added as a categorical variable. Even though 
age and obesity (as BMI) are generally considered as risk 
factors for a severe COVID-19, the correlations were 
not informative in our models. Strikingly, no item in the 
patients’ medical history carried enough information to 
be included in the final predictors.
Validation cohort
During the period between September 1st and November 
16th 2020, 18′472 patients received SARS-CoV-2 test-
ing. General research consent was rejected by 731. Of 
the 2′679 eligible patients testing positive, sufficient data 
was available for 459 patients (141 out-patients and 318 
in-patients). The final validation data set consisted of 105 
severe and 354 non-severe cases. Detailed information is 
presented in Table 1.
COVID‑19 severity assessment score
Of the commonly measured laboratory parameters 
included in the predictive models, sodium, CRP, glucose 
and leucocytes were positively correlated with severe 
COVID-19, indicating that higher values pose a higher 
risk for worse outcomes. Hemoglobin and eGFR were 
negatively correlated with severe outcomes. The AUROC 
for the 30 internal validation folds ranged from 0.84 to 
0.98 (Fig.  3), indicating that the chosen parameters and 
cut-offs were good predictors for the endpoint. The final 
score allocation is shown in Table  1 with the compari-
son of the AUROC for the complete study and validation 
cohort in Fig. 2. The percentage of severe and non-severe 
courses per total score of all patients with laboratory val-
ues (including those with missing values) for the study 
and validation cohort is shown in Additional file 2: Fig-
ure S2. Based on the distribution, a total score of up to 3 
was associated with no cases of severe COVID-19 in the 
training cohort, (i.e. a specificity of 100%) thus represent-
ing a low risk. A score of 4 or 5 was associated with < 50% 
severe cases thus indicating a moderate risk, while 6 to 
7 points were associated with > 50% severe cases (high 
risk), and 8 or more points correlated with a very high 
risk to develop a severe COVID-19 (100% of the patients 
with severe disease, i.e. 100% sensitivity) (Table 2). 
External prospective validation was done without 
changes to the original models, i.e. with no recalibration. 
The score performed consistent with findings from the 
internal validation: the measured metrics in the valida-
tion cohort were lower (AUROC 0.85, positive predic-
tion value (PPV) 0.91, negative prediction value (NPV) 
0.81) than in the training cohort (AUROC 0.94, PPV 0.97, 
NPV 0.80), but still showed a very good predictivity. No 
patient with 0 score points developed a severe COVID-
19, patients with 6 or less score points developed a severe 
course in less than 50% of the cases, while at 7 and 8 
score points more than 50% showed a severe COVID-19. 
Patients with 9 or more score points were severely ill in 
90% of the cases. The correlation coefficient of the chosen 
laboratory parameters was in general lower in the valida-
tion cohort than in the training cohort, but the ranking of 
the parameters was in good agreement with the training 
cohort (see Additional file 1: Figure S1–3).
Machine learning models
The results of the internal validation of the different ML 
models are shown in Fig. 3, with median AUROC values 
ranging from 0.86 (DTI) to 0.96 (SVM). The employed 
ML models were well suited to distinguish between 
severe and non-severe COVID-19 with the laboratory 
parameters provided. The results of the external valida-
tion of the original models in Additional file 3: Figure S3 
suggest that the ML algorithms produced predictive and 
generalizable models.
Discussion
In this study, we created a clinical score and ML models 
that accurately predicted the likelihood of severe disease 
courses (defined as requiring ICU admission at any stage 
during the disease and/or death of any cause during the 
study period) for SARS-CoV-2 positive patients at the 
largest hospital group in Switzerland during the country’s 
‘first wave’ of the COVID-19 pandemic. An external vali-
dation using the larger ‘second wave’ patient cohort also 
confirmed the prognostic value of the score and models, 
and thus the generalizability.
The most predictive risk factors were male sex, low 
hemoglobin (< 100  g/L), elevation of inflammatory 
parameters (CRP > 25  mg/L, leucocyte counts > 10  G/L), 
hyperglycemia (> 10  mmol/L), and impaired renal func-
tion (eGFR < 75  mL/min, sodium > 144  mmol/L). Since 
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Table 1 General characteristics and  laboratory parameters of  the  training cohort (n = 198) and  validation cohort 
(n = 459)
Training cohort (N = 198) Validation cohort (N = 459)
Severe (N = 63) Non‑severe (N = 135) P value Severe (N = 105) Non‑severe (N = 354) P value
Demographics
 Age (years)
  Median (IQR) 65.0 (53.5, 79.5) 54.0 (36.0, 71.5)  < 0.002a 69.0 (61.0, 79.0) 62.0 (46.0, 75.0)  < 0.002a
 Sex
  Female, n (%) 11 (17.46%) 69 (51.11%)  < 0.002b 33 (31.43%) 150 (42.49%) 0.055b
 Hospitalization
  Inpatients, n (%) 61 (96.83%) 84 (62.22%)  < 0.002b 102 (97.14%) 216 (61.19%)  < 0.002b
 Deaths
  Deceased, n (%) 25 (39.68%) 0 (0.00%)  < 0.002b 33 (31.43%) 0 (0.00%)  < 0.002b
 Weight (kg)
  Median (IQR) 83.00 (70.40, 97.00) 75.65 (62.00, 87.00) 0.241a 80.60 (70.00, 90.15) 77.20 (65.70, 87.00) 0.989a
 Height (cm)
  Median (IQR) 172.00 (165.00, 178.25) 170.00 (163.00, 177.00) 0.012a 170.00 (165.00, 176.00) 170.00 (164.00, 176.00) 0.037a
 Body Mass Index (BMI, kg/m2)
  Median (IQR) 27.62 (24.80, 31.57) 25.82 (22.52, 28.95) 0.018a 28.10 (24.95, 32.62) 26.23 (23.62, 29.59)  < 0.002a
Laboratory parameters
 Maximal CRP levels
  Median (IQR) 176.00 (92.75, 279.75) 22.00 (6.00, 67.00)  < 0.002a 146.00 (72.75, 228.25) 35.00 (8.00, 89.00)  < 0.002a
 Maximal sodium levels
  Median (IQR) 142.00 (139.50, 146.00) 139.00 (136.00, 141.00)  < 0.002a 142.00 (139.00, 145.00) 139.00 (137.00, 141.00)  < 0.002a
 Minimal hemoglobin levels
  Median (IQR) 96.00 (78.25, 115.00) 132.00 (119.00, 141.00)  < 0.002a 110.00 (86.00, 122.00) 128.00 (116.00, 141.00)  < 0.002a
 Minimal glomerular filtration rate (GFR) values
  Median (IQR) 53.00 (25.00, 85.50) 87.00 (72.00, 104.00)  < 0.002a 62.50 (32.50, 81.00) 82.00 (59.00, 98.00)  < 0.002a
 Maximal glucose values
  Median (IQR) 10.10 (8.00, 12.75) 6.10 (5.48, 7.62)  < 0.002a 10.70 (8.30, 13.50) 6.42 (5.60, 8.20)  < 0.002a
 Maximal leukocytes values
  Median (IQR) 10.60 (7.83, 17.55) 5.92 (4.70, 7.77)  < 0.002a 12.30 (8.95, 16.00) 6.73 (4.97, 8.78)  < 0.002a
Comorbidities
 Substance use
  Smoker, n (%) 11 (17.46%) 16 (11.85%) 0.400b – – –
  Alcohol, n (%) 5 (7.94%) 11 (8.15%) 1b – – –
 Cardiovascular disorders
  Cardiovascular disorders, 
overall, n (%)
47 (74.60%) 56 (41.48%)  < 0.002b – – –
  Arterial hypertension, n (%) 35 (55.56%) 43 (31.85%) 0.003b – – –
  Coronary heart disease, 
n (%)
13 (20.63%) 6 (4.44%)  < 0.002b – – –
  Congestive heart failure and 
cardiomyopathy, n (%)
16 (25.40%) 14 (10.37%) 0.011b – – –
  Stroke, n (%) 8 (12.70%) 11 (8.15%) 0.451b – – –
  Other, n (%) 16 (25.40%) 24 (17.78%) 0.292b – – –
 Pulmonary disorders
  Pulmonary disorders, over-
all, n (%)
18 (28.57%) 35 (25.93%) 0.826b – – –
  Asthma, n (%) 4 (6.35%) 15 (11.11%) 0.423b – – –
  Chronic obstructive pulmo-
nary disease (COPD), n (%)
6 (9.52%) 5 (3.70%) 0.183b – – –
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most of those parameters are readily available/commonly 
measured at presentation, the score can provide early-
stage guidance regarding patient triage, thus contributing 
to the improvement of outcomes by enabling timely and 
targeted use of health care resources for patients at risk 
for severe clinical courses.
Regarding the individual laboratory score compo-
nents, an increase in inflammatory parameters as a pre-
dictor of severe disease is mechanistically plausible and 
well documented [19–22]. Similar to other infections, 
loss of glycemic control has been reported in COVID-19 
patients (with elevated blood glucose increasing the risk 
of SARS-CoV-2 infection), and also that well controlled 
diabetes mellitus correlates with favorable outcomes [23, 
24]. A systematic review and meta-analysis further cor-
roborated these findings [25]. There is ample evidence 
that end-stage kidney disease and renal impairment (as 
reflected by eGFR in our analysis) are prognostic of more 
severe disease, with case fatality rates on ICU of up to 
50% [26, 27]. Similarly, electrolyte disorders like hyperna-
tremia have been linked to increased COVID-19 related 
mortality, possibly in relation to increased respiratory 
rate or dehydration from increased body temperature 
[28, 29]. Finally, a systematic review and meta-analysis 
recently discussed the role of anemia and changes in 
iron metabolism, reflected by the low-normal cut-off for 
Laboratory values were considered from 3 day prior to until 1 day after the first positive SARS-CoV-2 PCR test result; italic numbers indicate significant differences 
(p < 0.05) between severe and non-severe cases.
IQR interquartile range
a Wilcoxon rank sum test
b Chi Square test
Table 1 (continued)
Training cohort (N = 198) Validation cohort (N = 459)
Severe (N = 63) Non‑severe (N = 135) P value Severe (N = 105) Non‑severe (N = 354) P value
 Other, n (%) 10 (15.87%) 19 (14.07%) 0.906b – – –
 Other disorders
  Type II diabetes (incl. predia-
betes), n (%)
22 (34.92%) 20 (14.81%) 0.002b – – –
  Cancer, n (%) 6 (9.52%) 16 (11.85%) 0.808b – – –
Table 2 COVID-19 severity assessment (COSA) score parameters and evaluation
Laboratory parameters are maximal (C-reactive protein (CRP), sodium, glucose, leucocytes) or minimal (estimated glomerular filtration rate (eGFR) according to the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)) values 3 days prior to and up to 1 day after first positive SARS-CoV-2 testing. % patients: fraction of 
patients per category, % severe: fraction of patients with severe outcomes per category
Parameter Value Score points
Sex Male 1
CRP  ≥ 25 mg/L 3
Sodium  ≥ 144 mmol/L 2
Hemoglobin  ≤ 100 g/L 1
eGFR according to CKD-EPI  ≤ 75 mL/min 1
Glucose  ≥ 8.6 mmol/L 1
Leucocytes  ≥ 10 G/L 1
Score evaluation
Total score per patient Category % patients (training, 
validation)
% severe outcome 
(training, 
validation)
0–3 points: Low risk for severe COVID-19 (< 5%) 37.9, 38.4% 0, 4.5%
4–5 points: Moderate risk for severe COVID-19 (< 50%) 34.8, 32.5% 24.6, 15.4%
6–7 points: High risk for severe COVID-19 (> 50%) 12.1, 19.4% 70.8, 46.1%
8–10 points: Very high risk for severe COVID-19 (> 90%) 15.2, 9.6% 96.7, 75.0%
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hemoglobin in our analysis, in the pathophysiology and 
disease course of COVID-19 [30].
One of the hallmarks of COVID-19 is its dispropor-
tionally high mortality in the elderly, possibly due to 
multimorbidity [31, 32]. More detailed surveys report 
an increased likelihood of death following development 
of symptoms in the age groups < 30 years     and > 65y 
years [33]. It has been speculated that younger patients 
with severe courses experience hyperinflammatory syn-
dromes (often referred to as ‘cytokine storms’), an IL-6 
driven over-reaction of the immune system to pathogens 
resulting in multi-organ failure that is associated with a 
high mortality [34]. Several studies identified high age 
and obesity, which are often connected to a reduced state 
of health, as risk factor for severe COVID-19 [35, 36]. 
Therefore, these parameters are not independent risk 
factors in our cohort despite statistically significant dif-
ferences between the means, arguably because of their 
correlation with multimorbidity. To avoid overfitting due 
to intercorrelated parameters, we rejected age and obe-
sity (as BMI) in favor of other correlated features that 
also explain additional cases.
There is also a large body of evidence concerning 
underlying diseases as risk factors associated with criti-
cal disease and overall COVID-19 mortality [37–39]. 
We screened the EHRs for presence of cardiovascular 
comorbidities (incl. arterial hypertension and stroke 
events), obesity, chronic pulmonary conditions, kidney 
disease, cancer, diabetes mellitus, and smoking status. Of 
those, only cardiovascular disease (overall, hypertension, 
Fig. 2 Area under the receiver operating characteristic (AUROC) of 
the COVID-19 severity assessment (COSA) score. Training cohort (red, 
internal) and validation cohort (blue, external)
Fig. 3 Performance of the clinical risk stratification COVID-19 severity assessment (COSA) score and machine learning models. Performance on 
training data as measured by area under the receiver operating characteristic. DTI (CART): decision tree induction with classification and regression 
trees. The lower and upper hinges of the box correspond to interquartile ranges (IQR). The upper and lower whisker extends from the hinge to the 
largest and smallest value, respectively, no further than 1.5 * IQR from the hinge. Data beyond the end of the whiskers are plotted individually
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coronary heart disease, and cardiomyopathy or chronic 
heart failure), and type II diabetes had a prognostic value. 
However, none of those parameters were more predic-
tive than male sex and laboratory values taken around 
the time of first RT-PCR. Hyperglycemia, anemia, and 
impaired renal function are signs or risk factors for dete-
rioration and poor prognosis of these comorbidities in 
their own right, and may indicate that poorly controlled 
underlying diseases are more detrimental than the dis-
eases themselves.
In the light of the worldwide spread of SARS-CoV-2 
leading to high rate of fatalities and shortage of hospi-
tal beds in many countries, several attempts have been 
undertaken to create predictive scores and models for 
the early identification of patients at high risk. In a regu-
larly updated systematic review by Wynants et al. [40], 50 
prognostic models were identified, including 23 for mor-
tality and 8 for progression to severe disease. Frequently 
reported prognostic variables were sex, comorbidities, 
CRP and creatinine. All models reported moderate to 
excellent predictive performance, but were judged as 
being at high risk of bias (e.g. due to exclusion of partici-
pants still in follow-up who didn’t develop the outcome 
at the end of the study, and use of the last available meas-
urement instead of one at the time of intended use of the 
model), and none of them is currently recommended 
for use in clinical practice [40]. Recommendations for 
future investigations in this field include adequate inclu-
sion/censoring and description of the study population, 
specification of the time horizon of the prediction, and 
structured reporting based on the Transparent Reporting 
of a multivariable prediction model for Individual Prog-
nosis or Diagnosis (TRIPOD) guidelines [41] to enable 
independent validation, which we aimed to follow closely 
with this study.
Limitations of the current study include the small 
sample size, and the exclusion of patients who rejected 
the IHG general research consent and those with no 
laboratory data available. The excluded 379 individuals 
(65.7% of the total of 577 patients who did not reject 
the general research consent and were tested positive) 
correspond mostly to patients seen in the ambulatory 
COVID-19 testing facility, where the general pub-
lic have access to on-demand testing. Furthermore, 
more of the included patients were hospitalized, while 
comorbidities and risk factors might differ among indi-
viduals who could be treated as out-patients. There was 
no specific time-to-event analysis, particularly since 
the data generated in the first months of the pandemic 
was very heterogeneous, and included external direct 
transfers to ICU. The score and models therefore only 
speak to the probability of incurring a severe outcome, 
not when this outcome will occur. Another limitation 
concerns the censoring of outcomes, given there was 
no explicit follow-up. While it is conceivable that out-
patients in particular could have deteriorated after dis-
charge and presented elsewhere, the large catchment 
area of the IHG should mitigate this effect. Addition-
ally, the case-fatality ratios of 12.6%, and 7.2% in the 
training group (‘first wave’) and the prospective valida-
tion group (‘second wave’), respectively, are high com-
pared to the Swiss national average (1.1%, https ://covid 
19.bag.admin .ch). This hints at good coverage of out-
comes in these retrospective analyses along with pres-
ence of an admission bias. We therefore suggest using 
the tools proposed here for projection of outcomes as 
discussed.
Conclusion
In conclusion, based on the findings of the study includ-
ing external validation, the COSA score and ML models 
based on commonly available laboratory values can help 
predict the likelihood of a severe clinical course early on 
during COVID-19 disease, thus allowing stratification to 
treatment regimens and identification of patients who 
should be put under close monitoring to detect early 
deterioration. Future validations could include other hos-
pital centers as well as general practitioners.
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